Phase 0 (early-phase) clinical trial repurposing anti-retroviral drugs to treat NF2 related tumours RETREAT.

Phase 0 clinical trial. In this early-phase clinical trial, NF2 patients with skin schwannomas are being treated with HIV drugs for 30 days. Blood and tissue samples are collected before and after treatment to assess drug uptake, evaluate the drugs' impact on tumour cells, and monitor changes in blood biomarkers. This comprehensive approach will help identify the minimal effective dose and establish the biologically active dose, providing critical data for larger clinical trials.